.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

FAMVIR Drug Profile

« Back to Dashboard
Famvir is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in twenty-eight countries.

The generic ingredient in FAMVIR is famciclovir. There are eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the famciclovir profile page.

Summary for Tradename: FAMVIR

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: FAMVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
FAMVIR
famciclovir
TABLET;ORAL020363-003Dec 11, 1995RXNo5,840,763*PED► subscribeY► subscribe
Novartis
FAMVIR
famciclovir
TABLET;ORAL020363-001Apr 26, 1996RXNo5,916,893*PED► subscribeY► subscribe
Novartis
FAMVIR
famciclovir
TABLET;ORAL020363-003Dec 11, 1995RXNo5,916,893*PED► subscribeY► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FAMVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
FAMVIR
famciclovir
TABLET;ORAL020363-003Dec 11, 19956,124,304*PED► subscribe
Novartis
FAMVIR
famciclovir
TABLET;ORAL020363-003Dec 11, 19955,916,893*PED► subscribe
Novartis
FAMVIR
famciclovir
TABLET;ORAL020363-002Jun 29, 19945,246,937*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FAMVIR

Drugname Dosage Strength RLD Submissiondate
famciclovirTablets125 mg, 250 mg and 500 mgFamvir12/28/2004

International Patent Family for Tradename: FAMVIR

Country Document Number Estimated Expiration
Bulgaria101608► subscribe
United Kingdom9506663► subscribe
African Regional IP Organization (ARIPO)9701001► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FAMVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0036Belgium► subscribePRODUCT NAME: FAMCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21325 19960708; FIRST REGISTRATION: GB - 10592/0035 19931210
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc